**Summary**
Faron Pharmaceuticals Ltd. has received positive feedback from the U.S. Food and Drug Administration (FDA) regarding its proposed clinical development plan for **bexmarilimab**, a novel precision cancer immunotherapy. The FDA endorsed an **accelerated approval pathway** for bexmarilimab in **treatment-naïve (frontline) higher-risk myelodysplastic syndrome (HR-MDS)**, focusing on **Complete Response (CR) + CR equivalent (CReq)** per **IWG 2023 criteria** and **Overall Survival (OS)** as co-primary endpoints. This follows a successful end-of-phase 2 (EOP2) meeting with the FDA, which advised Faron to prioritize frontline development to maximize the drug’s potential across the entire HR-MDS indication.
The planned **registrational Phase 2/3 trial** will evaluate bexmarilimab in combination with **azacitidine** in frontline HR-MDS patients. The trial will begin with a dose optimization run-in period comparing 1 mg/kg and 3 mg/kg regimens with placebo, followed by a seamless transition into the registrational stage. An interim analysis will support accelerated approval based on CR + CReq data.
Key highlights include
FDA acceptance of IWG 2023 criteria as a primary endpoint, marking the first registrational trial to do so.
Bexmarilimab’s novel mechanism of action, targeting **Clever-1** to reprogram macrophages and enhance immune response.
Potential for transformative treatment in an area of significant unmet medical need.
Faron’s CEO, Dr. Juho Jalkanen, emphasized the milestone as a major regulatory de-risking step, bringing bexmarilimab closer to approval. Dr. Amer Zeidan, a leading expert in hematologic malignancies, praised the FDA’s acceptance of IWG 2023 criteria as more patient-centric and clinically meaningful compared to older standards.
This development positions Faron as a leader in advancing immunotherapy for HR-MDS, with bexmarilimab poised to address critical treatment gaps in this aggressive hematological malignancy.